{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:21:45Z","timestamp":1793420505615,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"\u201cGreen talent\u201d Program","award":["QML20231201"],"award-info":[{"award-number":["QML20231201"]}]},{"name":"National Natural Resources Foundation of China","award":["82302064"],"award-info":[{"award-number":["82302064"]}]},{"name":"National Natural Resources Foundation of China","award":["81900004"],"award-info":[{"award-number":["81900004"]}]},{"name":"National Natural Resources Foundation of China","award":["32200711"],"award-info":[{"award-number":["32200711"]}]},{"name":"National Key Research and Development Program of China","award":["2023YFC2508500"],"award-info":[{"award-number":["2023YFC2508500"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Influenza virus infection can lead to high mortality and severe disease complicated by secondary bacterial pneumonia. FeiyanHeji (FyHj) is a traditional Chinese medicine (TCM) mixture used clinically to treat pneumonia caused by influenza, although its mechanism of action remains unclear. We first conducted a network pharmacology analysis of the ten components in FyHj to predict their potential interactions with influenza-related targets. GO and KEGG analyses revealed significant enrichment in the inflammatory response, ubiquitin protein binding, RNA virus-related pathways, and the RIG-I signaling pathway, suggesting these may be involved in the anti-influenza process. Further experimental validation demonstrated that FyHj inhibits viral replication through two mechanisms: (1) promoting the degradation of polymerase acidic (PA) protein by interfering with UBP11-mediated K48-linked deubiquitination, and (2) enhancing antiviral innate immunity by upregulating the RIG-I\/MAVS signaling pathway and stabilizing MAVS through inhibition of TRIM25-mediated K48-linked ubiquitination of MAVS. Finally, FyHj was observed to reduce lung viral load and inflammation in mice infected with influenza A virus (IAV). In conclusion, FyHj decoction elicits potent antiviral effects through multiple mechanisms, providing a mechanistic basis for the clinical application of FyHj and highlighting its potential as a source for multi-target anti-influenza therapies.<\/jats:p>","DOI":"10.1186\/s13020-026-01372-6","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:27:50Z","timestamp":1776828470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["FeiyanHeji multifunctionally inhibits influenza virus via PA protein degradation and RIG-I signaling pathway potentiation"],"prefix":"10.1186","volume":"21","author":[{"given":"Tongtong","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"1","key":"1372_CR1","volume":"8","author":"P Ep","year":"2020","unstructured":"Ep P, et al. Immune pressure on polymorphous Influenza B populations results in diverse hemagglutinin escape mutants and lineage switching. Vaccines. 2020;8(1):89.","journal-title":"Vaccines"},{"issue":"4","key":"1372_CR2","volume":"7","author":"SD Jazayeri","year":"2019","unstructured":"Jazayeri SD, Poh CL. Development of universal influenza vaccines targeting conserved viral proteins. Vaccines (Basel). 2019;7(4):56.","journal-title":"Vaccines (Basel)"},{"issue":"8045","key":"1372_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41586-024-08054-z","volume":"637","author":"TP Peacock","year":"2025","unstructured":"Peacock TP, et al. The global H5N1 influenza panzootic in mammals. Nature. 2025;637(8045):304\u201313.","journal-title":"Nature"},{"issue":"1","key":"1372_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s00018-025-05733-6","volume":"82","author":"Y Liao","year":"2025","unstructured":"Liao Y, et al. USP1 inhibits influenza A and B virus replication in MDCK cells by mediating RIG-I deubiquitination: Liao et al. Cell Mol Life Sci. 2025;82(1):200.","journal-title":"Cell Mol Life Sci"},{"key":"1372_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2025.112037","volume":"224","author":"S Li","year":"2025","unstructured":"Li S, et al. IRF1-RIG-I signaling defects in the aged alveolar epithelial cells may contribute to decreased pulmonary antiviral immune responses. Mech Ageing Dev. 2025;224:112037.","journal-title":"Mech Ageing Dev"},{"issue":"9","key":"1372_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/14656566.2024.2370895","volume":"25","author":"M Bassetti","year":"2024","unstructured":"Bassetti M, et al. Treating influenza with neuraminidase inhibitors: an update of the literature. Expert Opin Pharmacother. 2024;25(9):1163\u201374.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1372_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2429627","volume":"13","author":"J Xu","year":"2024","unstructured":"Xu J, et al. Influenza neuraminidase mutations and resistance to neuraminidase inhibitors. Emerg Microbes Infect. 2024;13(1):2429627.","journal-title":"Emerg Microbes Infect"},{"key":"1372_CR8","first-page":"45","volume":"7","author":"Y Abed","year":"2020","unstructured":"Abed Y, et al. Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient. Antivir Ther. 2020;7:45.","journal-title":"Antivir Ther"},{"key":"1372_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.4AB0420-694R","author":"P Cheung","year":"2020","unstructured":"Cheung P, et al. PB1-F2 protein of highly pathogenic Influenza A (H7N9) virus selectively suppresses RNA-induced NLRP3 inflammasome activation through inhibition of MAVS-NLRP3 interaction. J Leukoc Biol. 2020. https:\/\/doi.org\/10.1002\/JLB.4AB0420-694R.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"1372_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jiac.2023.10.017","volume":"30","author":"C Shiraishi","year":"2024","unstructured":"Shiraishi C, et al. Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: a systematic review and meta-analysis. J Infect Chemother. 2024;30(3):242\u20139.","journal-title":"J Infect Chemother"},{"key":"1372_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1428095","volume":"15","author":"J Cai","year":"2024","unstructured":"Cai J, et al. Real-world effectiveness and safety of baloxavir marboxil or oseltamivir in outpatients with uncomplicated influenza A: an ambispective, observational, multi-center study. Front Microbiol. 2024;15:1428095.","journal-title":"Front Microbiol"},{"issue":"2","key":"1372_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00705-024-06214-0","volume":"170","author":"R Arvia","year":"2025","unstructured":"Arvia R, et al. High-resolution melting analysis for detection of nucleotide mutation markers in the polymerase-acidic (PA) gene of influenza virus that are associated with baloxavir marboxil resistance. Arch Virol. 2025;170(2):29.","journal-title":"Arch Virol"},{"issue":"1","key":"1372_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2341144","volume":"13","author":"N Chen","year":"2024","unstructured":"Chen N, et al. Viral strategies to antagonize the host antiviral innate immunity: an indispensable research direction for emerging virus-host interactions. Emerg Microbes Infect. 2024;13(1):2341144.","journal-title":"Emerg Microbes Infect"},{"key":"1372_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.157033","author":"Y-L Sun","year":"2025","unstructured":"Sun Y-L, et al. Elimination of gut microbiota hinders the therapeutic effect of amentoflavone on respiratory syncytial virus-induced lung inflammation injury by regulating innate immunity. Phytomedicine. 2025. https:\/\/doi.org\/10.1016\/j.phymed.2025.157033.","journal-title":"Phytomedicine"},{"issue":"1","key":"1372_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13020-024-00977-z","volume":"19","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. Astragali radix (Huangqi): A time-honored nourishing herbal medicine. Chin Med. 2024;19(1):119.","journal-title":"Chin Med"},{"key":"1372_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24437","author":"A Tu","year":"2024","unstructured":"Tu A, et al. Evaluate the clinical efficacy of traditional Chinese Medicine as the neoadjuvant treatment in reducing the incidence of hepatocellular carcinoma in patients with Hepatitis B-related cirrhosis: a systematic review and meta-analysis. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24437.","journal-title":"Heliyon"},{"key":"1372_CR17","doi-asserted-by":"publisher","DOI":"10.2174\/0122150838304552241129094342","author":"P Chen","year":"2025","unstructured":"Chen P, et al. An overview of Traditional Chinese Medicine nursing for patients with COVID-19. Curr Tradit Med. 2025. https:\/\/doi.org\/10.2174\/0122150838304552241129094342.","journal-title":"Curr Tradit Med"},{"issue":"2","key":"1372_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.53388\/IDR2024008","volume":"5","author":"J Hou","year":"2024","unstructured":"Hou J, Wang G, Xu S. Etiology and pathogenesis of Coronavirus disease 2019 on the view of Chinese medicine. Infect Dis Res. 2024;5(2):8.","journal-title":"Infect Dis Res"},{"key":"1372_CR19","unstructured":"Mallick, O., et al., Role of Dietary Botanical Lead Compounds on Infectious Diseases."},{"issue":"6","key":"1372_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.15585\/mmwr.mm6606a2","volume":"66","author":"L Blanton","year":"2017","unstructured":"Blanton L, et al. Update: Influenza activity\u2014United States, October 2, 2016\u2013February 4, 2017. Morb Mortal Wkly Rep. 2017;66(6):159\u201366.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"50","key":"1372_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023217","volume":"99","author":"L Wei","year":"2020","unstructured":"Wei L, et al. A randomized, double-blind, placebo-controlled, multicenter clinical trial for efficacy and safety of traditional Chinese medicine combined with antibiotics in the treatment of bacterial pneumonia in children. Medicine. 2020;99(50):e23217.","journal-title":"Medicine"},{"issue":"49","key":"1372_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023284","volume":"99","author":"J Chen","year":"2020","unstructured":"Chen J, et al. Efficacy and safety of Maxing Shigan Decoction in the treatment of chronic obstructive pulmonary disease: A protocol for a systematic review and meta-analysis. Medicine. 2020;99(49):e23284.","journal-title":"Medicine"},{"key":"1372_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.113854","volume":"271","author":"Y Li","year":"2021","unstructured":"Li Y, et al. Potential effect of Maxing Shigan decoction against Coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification. J Ethnopharmacol. 2021;271:113854.","journal-title":"J Ethnopharmacol"},{"issue":"8","key":"1372_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nrmicro.2016.87","volume":"14","author":"AJ Te Velthuis","year":"2016","unstructured":"Te Velthuis AJ, Fodor E. Influenza virus RNA polymerase: Insights into the mechanisms of viral RNA synthesis. Nat Rev Microbiol. 2016;14(8):479\u201393.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"1372_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.bj.2018.08.004","volume":"41","author":"L Denney","year":"2018","unstructured":"Denney L, Ho LP. The role of respiratory epithelium in host defence against influenza virus infection. Biomed J. 2018;41(4):218\u201333.","journal-title":"Biomed J"},{"issue":"7","key":"1372_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071722","volume":"10","author":"EA Moreira","year":"2021","unstructured":"Moreira EA, Yamauchi Y, Matthias P. How influenza virus uses host cell pathways during uncoating. Cells. 2021;10(7):1722.","journal-title":"Cells"},{"issue":"7","key":"1372_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.7326\/0003-4819-156-7-201204030-00411","volume":"156","author":"J Hsu","year":"2012","unstructured":"Hsu J, et al. Antivirals for treatment of influenza: A systematic review and meta-analysis of observational studies. Ann Intern Med. 2012;156(7):512\u201324.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1372_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao L, et al. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther. 2022;7(1):113.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1372_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41422-020-0362-1","volume":"31","author":"P Hou","year":"2021","unstructured":"Hou P, et al. A novel selective autophagy receptor, CCDC50, delivers K63\u00a0polyubiquitination-activated RIG-I\/MDA5 for degradation during viral infection. Cell Res. 2021;31(1):62\u201379.","journal-title":"Cell Res"},{"issue":"1","key":"1372_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.molcel.2022.11.018","volume":"83","author":"DT Thoresen","year":"2023","unstructured":"Thoresen DT, et al. A rapid RIG-I signaling relay mediates efficient antiviral response. Mol Cell. 2023;83(1):90\u2013104.","journal-title":"Mol Cell"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01372-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-026-01372-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01372-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:27:57Z","timestamp":1776828477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-026-01372-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1372"],"URL":"https:\/\/doi.org\/10.1186\/s13020-026-01372-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7954179\/v1","asserted-by":"object"}]},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experimental procedures were performed according to protocols approved by the Institutional Ethics Committee of Institute of Microbiology, Chinese Academy of Sciences (NO: SQIMCAS2022120).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}